Editorial Commentary
When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?
Abstract
The first U.S. Food and Drug Administration (FDA) approval of a programmed cell death protein (PD-1) inhibitor specifically for advanced gastroesophageal cancer occurred with the passing of pembrolizumab on September 22, 2017 (1).
